Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Phase Scientific International Ltd. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners and 2 distinct art units, showing that pending cases are being handled by different examiners in separate technical units. This distribution suggests that the company biotechnology applications cover distinct sub-fields.
The busiest examiner is VANN-OJUEKAIYE, KENDRA RAYCHELL, who is responsible for 1 busiest_examiner_pending. This represents a portion of the 2 pending office actions currently active for the portfolio. Since there are 2 distinct examiners, the workload is distributed, with examiners overseeing the 2 pending office actions.
The presence of 2 distinct art units means that the prosecution must navigate the specific procedural expectations of different supervisory groups. The 2 pending office actions will be influenced by the individual examination style of the 2 distinct examiners. VANN-OJUEKAIYE, KENDRA RAYCHELL is an examiner currently managing 1 busiest_examiner_pending in the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
| CREWS, JARET JAMES | 1 | 44.7% | +70.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18463312 | METHODS AND KITS FOR ISOLATING TARGET NUCLEIC ACIDS BELOW A TARGET SIZE FROM A SAMPLE | VANN-OJUEKAIYE, KENDRA RAYCHELL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17753178 | METHOD, COMPOSITION AND KIT FOR SIZE SELECTIVE ENRICHMENT OF NUCLEIC ACIDS | CREWS, JARET JAMES | 72d |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18463312 | METHODS AND KITS FOR ISOLATING TARGET NUCLEIC ACIDS BELOW A TARGET SIZE FROM A SAMPLE | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112DP | Final Rejection | — | Pending | Sep 08, 2023 |
| 17753178 | METHOD, COMPOSITION AND KIT FOR SIZE SELECTIVE ENRICHMENT OF NUCLEIC ACIDS | CREWS, JARET JAMES | 1691 | §103 | Non-Final OA | 72d | Pending | Feb 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial